Samsung Bioepis CEO urges patience as US biosimilar market lags

Samsung Bioepis CEO urges patience as US biosimilar market lags

Source: 
BioPharma Dive
snippet: 

"People are too impatient with the current launch status of biosimilars," Ko said in an interview with BioPharma Dive this month. "Market shaping takes time."